CRLNYSESEC EDGAREDGAR

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Services-Commercial Physical & Biological Research·WILMINGTON, MA·FY end 12/27·CIK 1100682

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$4.0B$4.0B$4.1B$4.0B$3.5B
Gross Profit——————
Operating Income$25.2M$227.3M$617.3M$651.0M$589.9M
Net Income-$144.3M$22.2M$474.6M$486.2M$391.0M
Operating CF$737.6M$734.6M$683.9M$619.6M$760.8M
Capex——————
Free Cash Flow——————
Buybacks$360.7M$119.2M$24.2M$38.7M$40.7M
Dividends——————
Gross Margin——————
Operating Margin0.6%5.6%14.9%16.4%16.7%
Net Margin-3.6%0.5%11.5%12.2%11.0%
FCF Margin——————
R&D / Revenue——————
Effective Tax-42.9%72.8%17.4%20.9%17.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Services-Commercial Physical & Biological Research · 1 peer
CEO Pay Ratio
CRL
251:1
INCY
47:1
CEO total comp
CRL
—
INCY
—
Net Margin
CRL
-3.6%
INCY
25.0%